1. Global Vaccines 202X: Access, Equity, EthicsNovartis Vaccines & Diagnostics Clement Lewin PhD MBA Head Medical Affairs & Policy Region North America Philadelphia; May 5th, 2011 | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

2. Novartis Vaccines & Diagnostics Overview • Leading manufacturer of influenza, pediatric, and meningitis vaccines • Globally produce over 500 million doses of vaccine, 70% to developing countries • Invested over $2 bn in vaccine production since 2006 including large partner with HHS on Pandemic Influenza • Institute for global health (NVGH) launched in 2009 to develop vaccines for neglected diseases | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

3. Major global presenceNovartis Vaccines and Diagnostics locations Marburg Vaccines manufacturing Amsterdam Vaccines data management Liverpool Vaccines manufacturing Cambridge Global Leadership Center Basel Vaccines Emeryville Diagnostics headquarters & Vaccines administration Hong KongDiagnostics Holly Springs Vaccines manufacturing Singapore Vaccines Siena/Rosia Vaccines manufacturing,R&D Paris Diagnostics Hyderabad Development Buenos AiresVaccines Ankleshwar Vaccines manufacturing ~5,000 Associates Worldwide* | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

4. Focus going forward is on new disease targets and increased global access Develop New Vaccines for Established Markets Develop New Vaccines for Global Unmet Needs NewDisease Targets Expand Access Globally Current Vaccine Market Vaccine Preventable Diseases Established Markets Developing Countries | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

5. m Expanding sustainable access in emerging markets is critical for a healthy vaccines industry Global Birth Cohort Distribution Estimate of Annual Births, m • Vast majority of births in Asia, Africa, LATAM • Many markets currently addressed through GAVI/UNICEF mechanisms (including AMCs) • Dramatic expansion in local and regional players • Multi-nationals will increasingly focus resources on expanding uptake in these markets inthe future North America Europe 4%(5) 7% (9) Africa LATAM 27%(35) 9%(11) 55%(72) Asia | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

6. Challenges will need to be overcome • Harmonizing regulatory pathways for new vaccine technologies and production platforms • Sustainable investment, cost, and pricing models to support access and innovation • Improving public perceptions of value proposition of newer generations of vaccines • Building continued faith in vaccines and their public health impact and benefits at the individual level | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics

7. | Global Vaccine 202X | C Lewin | May 5 2011 | Access Equity Ethics